10 thematic workbooks describing the national situation on drugs in France in 2023.
This report presents a new estimate of the social cost of drugs in France in 2019, following a previous calculation in 2010.
Among the range of cannabis regulatory systems introduced in North America, the example of British Columbia demonstrates a cautious regulatory approach, centred on the gradual introduction of cannabis on the market, which is designed to be reasonable and guided by a step-by-step evaluation of the reform.
Canada legalised cannabis for non-medical use in October 2018. While the federal government organises the production of cannabis, it has left it up to its 13 provinces and territories to define a distribution and retail model. Ontario, the most populous province and largest cannabis market in Canada, is at the forefront of this process.
Quebec was one of the most reluctant provinces when the federal government announced its decision to legalise cannabis for non-medical use.
In French Polynesia, a major concern has arisen in recent years about the use of methamphetamine, imported from the United States in the form of crystals, known as “ice”.
This 2022 edition provides an overall perspective digest in 8 pages with the most recent and detailed facts and figures.
The aim of this Théma is to provide an overview of the situations and problems currently observed in the French overseas territories with regard to drugs and addictions, based on the most recent statistical data and the main studies carried out in these territories.
This is a review and synthesis of the scientific literature on public health effects of liberalization of marijuana prohibition in the United States.
This report summarizes eight years of policy and public health knowledge since Colorado and Washington became the first states in the U.S. – and the first jurisdictions in the world – to begin to develop and implement policies around a commercial marketplace for marijuana.
This report analyzes the regulation of cannabis in Canada, as well as the political, economic and social impact of the policies adopted.
Since 1999, the OFDT has been quantifying the opinions and perceptions of the French population on drugs and related public policies through the EROPP survey (Survey on representations, opinions and perceptions regarding psychoactive drugs).
Studies on social cost allow public authorities to evaluate the economic burden of a social problem on the community.
Within the framework of the ERANID project (European Research Area Network on Illicit Drugs), funded by the European Commission (EC), the OFDT carried out a Europe-wide survey in the six member countries of the consortium (Belgium, France, Italy, the Netherlands, Portugal, the United Kingdom) and at the level of the EC.
Launched in March 2003 by then President Jacques Chirac, the first French Cancer Plan (2003-2007) embodied the government's renewed dedication to addressing this topic.
The aim of this document is to illustrate the different aspects of the situation of cannabis in France (consumption, market, risks and consequences, public policy, etc.).
This report tries to bring about some facts to answer three basic questions: how many people use drugs in France, as regards a single experience or a more regular one? Which users are in trouble? Which sanitary, social and legal damages are caused by these uses?
The fourth edition of this report provides a clearer picture of the extent and complexity of the drug problem, how it has evolved over the past few years, and the measures implemented. The aim of this document is to put all the available knowledge into perspective.
The Institute for Health Monitoring (InVS) recently published a two volume report entitled "Contribution to the Evaluation of the Policy for Risk Reduction: SIAMOIS".
These last years, synthetic drug use has been presented as a new phenomenon, whose consequences are impossible to foresee.